From $175 to $120: What Repligen’s Collapse Actually Repriced
Repligen fell from $175.77 to $115.30 in the span of roughly three months. Waters Corp, a comparable life sciences tools provider with similar end-mar…
Repligen fell from $175.77 to $115.30 in the span of roughly three months. Waters Corp, a comparable life sciences tools provider with similar end-mar…
On February 14, 2026, Palantir traded at $179.4 per Nasdaq closing data. By April it had shed nearly $49 — closing at $130.5, down 29% from its 52-wee…
On January 30, 2026, Boeing filed its 2025 10-K. $89.4 billion in revenue. $4.3 billion in operating income. The stock was sitting at $220 — about 13%…
Three weeks ago, reports surfaced that Tesla is developing a smaller, lower-cost SUV — a product line it shelved, then revived, then re-revived. The s…
A 2.48% rate increase just handed UnitedHealth a 9.4% single-day rally. The math on that trade deserves more scrutiny.
The dominant narrative after t…
Something shifted in the cruise trade this spring — not in the balance sheets, not in the booking curves, but in the feeling. The money coming back in…
$64.6 billion in capital expenditure — 22.9% of Microsoft’s fiscal 2025 revenue according to its annual report — is sitting in the ground as data cent…
Micron’s bull case rests on a belief the market formed during a shortage and hasn’t updated. The HBM scarcity narrative — supply constraints, hypersca…
$13.3 billion in operating income according to Netflix’s latest filing, 29.5% margin, stock at $99 — a Roman court just called Netflix’s price hikes “…
What happens to CVS’s economics if the vertical integration stops being vertical? Regulators are pulling at that thread right now.
The 2.48% Medicare…